Comparative studies of the kinetics of dissolution of medicines on the basis of clopidogrel
Generic medicines occupy dominant positions both in the pharmaceutical market of Ukraine and in industrial production by domestic pharmaceutical enterprises. The use of generic drugs in medical practice is of significant medical and social importance for expanding the accessibility of the general population to essential drugs. In Ukraine, more than twenty generic medicines based on clopidogrel, both foreign and domestic, are registered. All generic drugs containing clopidogrel bisulfate must comply with pharmaceutical bisulfate must comply with pharmaceutical equivalence, the kinetics of release of the active pharmaceutical ingredient using the Dissolution test in vitro, and pharmacokinetic parameters in vivo.
The aim of the work was to carry out comparative studies of the dissolution kinetics of four samples of generic drugs based on clopidogrel with the dissolution kinetics of the original drug Plavix®, to evaluate the similarity factor of dissolution profiles and to determine the effect of biopharmaceutical factors on the equivalence of generics. Comparative studies of the kinetics of dissolution were carried out by the in vitro method according to the «Dissolution» test using a device with a blade with a
rotation speed of 50 rpm, a dissolution medium with a pH value of 2.0 in a volume of 900 ml at a temperature of 37 ± 1 °C. The determination of the quantitative content of clopidogrel, which passed into the dissolution medium, was carried out by the method of adsorption spectrophotometry in the ultraviolet region at a wavelength of
about 240 ± 2 nm. Based on the data obtained, the dissolution profiles of the original drug Plavix® and the studied samples of generic drugs were constructed, the similarity of which was assessed by the value of the similarity factor. According to the research results, it was found that one sample of the generic drug proved its equivalence by the in vitro method to Plavix®, and three other samples of generics had differences in dissolution kinetics in comparison with the original drug. Biopharmaceutical factors were analyzed that could affect the dissolution kinetics of the studied generic drugs, from which the physicochemical characteristics of clopidogrel bisulfate, the qualitative and quantitative composition of excipients and the features of the technological process were determined.
Thus, on the basis of the comparative studies of the dissolution kinetics of drugs based on clopidogrel, generics were found that did not correspond to the in vitro equivalence according to the Dissolution test to the original drug, which could be due to the influence of a combination of biopharmaceutical factors.
The Global Use of Medicinein 2019 and Outlook to 2023 Forecasts and Areas to Watch. IQVIA Institute. January 2019. Source: https://informatori.it/wp-content/uploads/2019/03/the-global-use-of-medicine-in-2019-and-outlook-to-2023.pdf
Vyshnytska I. V., Trokhymchuk V. V. Marketynhovyi analiz okremykh hrup protydiabetychnykh likarskykh zasobiv, predstavlenykh na farmatsevtychnomu rynku Ukrainy // Farmats. zhurn. – 2017. – № 2. – S. 3–11. https://doi.org/10.32352/0367-3057.2.17.01
Vlasenko I. O., Davtian L. L. Active pharmaceutical ingredients in dermatological medicines of Ukrainian pharmaceutical market // Farmats. zhurn. – 2019. – № 1. – S. 9–19. https://doi.org/10.32352/0367-3057.1.19.01
Derzhavnyi formuliar likarskykh zasobiv Ukrainy. Vypusk dvanadtsiatyi. – К., 2020. – Rezhym dostupu: https://moz.gov.ua/uploads/ckeditor/документи/ Form_2020_основні%20розділи.pdf
Natsionalnyi perelik osnovnykh likarskykh zasobiv. Pershe vydannia. – К., 2016. – Rezhym dostupu; https://moz.gov.ua/uploads/0/290nacionalnij_perelik_ osnovnih_likarskih_ zasobiv.pdf
Derzhavnyi reiestr likarskykh zasobiv Ukrainy. – Rezhym dostupu: http://www.drlz.com.ua/
Nakaz MOZ Ukrainy vid 26. 08. 2005 № 426 u redaktsii vid 02. 08. 2019. – Rezhym dostupu: https://zakon.rada.gov.ua/laws/show/z1069-05
Setkyna S. B., Khyshova O. M., Zubkevych L. V. i dr. Vlyianye byofarmatsevtycheskykh faktorov na еkvyvalentnost in vitro vosproyzvodymіkh lekarstvennkh sredstv na osnove klopydohrelia // Vestn. farmatsyy. – 2014. – № 1 (63). – S. 33–38.
Derzhavna farmakopeia Ukrainy: v 3 ch. / DP «Ukrainskyi naukovyi farmakopeinyit sentry akosti likarskykh zasobiv», 2-e vyd. – Kharkiv: DP «Ukrainskyi naukovyi farmakopeinyit sentry akosti likarskykh zasobiv», 2015. – Т. 1. – 1128 s.
Derzhavna Farmakopeia Ukrainy: v 3 ch. / DP «Ukrainskyi naukovyi farmakopeinyit sentry akosti likarskykh zasobiv», 2-e vyd. – Kharkiv: DP «Ukrainskyi naukovyi farmakopeinyit sentry akosti likarskykh zasobiv», 2015. – Т. 3. – S. 610–612
Nastanova ST-MOZU 42-7.2:2018 «Likarski zasoby. Doslidzhennia bioekvivalentnosti». – Rezhym dostupu: https://www.dec.gov.ua/wp-content/ uploads/attitude/1.pdf
EMA/CHMP/ICH/493213/2018 «ICH M9 guideline on biopharmaceutics Classification system – based biowaivers» ЕМА. July 2020. Source: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m9
Yin X.-Z. et al. Visualization and quantification of deformation behavior of clopidogrel bisulfate polymorphs during tableting // Sci. Rep. – 2016. – V. 6. – P. 21770. https://doi.org/10.1038/srep21770 (2016)
Polymorfnaia forma hydrosulfata klopydohrelia. Pat. 002386 Evrazyiskyi: MKY S07D 495/04, A61K 31/4365. № 200001187. Zaiavl. 15. 06. 1998; Opubl. 25. 04. 2002, Biul. № 02.
This work is licensed under a Creative Commons Attribution 4.0 International License.